Literature DB >> 23946278

Clinical phenotypes of Chinese primary hyperparathyroidism patients are associated with the calcium-sensing receptor gene R990G polymorphism.

Guiyan Han1, Ou Wang, Min Nie, Yan Zhu, Xunwu Meng, Yingying Hu, Huaicheng Liu, Xiaoping Xing.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the distribution of the A986S and R990G polymorphisms of the calcium-sensing receptor (CASR) gene in the Chinese population and whether there is an association between genetic variants and the risk of developing primary hyperparathyroidism (PHPT) and its associated clinical phenotypes.
METHODS: A total of 164 Chinese Han PHPT patients (M/F: 51/113) and 230 healthy controls (M/F: 50/180) were enrolled. The common clinical parameters of PHPT patients including biochemical markers, bone mineral density (BMD), kidney stone occurrence, and pathology results were analyzed. Genotyping was conducted for both the patients and controls, and it was carried out using standard procedures.
RESULTS: The R990G variant was more frequently present than the A986S variant in this group of Chinese PHPT patients. The R allele increased the risk of PHPT (odds ratio=1.134, 95% CI: 1.008, 1.277, and P=0.036). Patients with either the RR or RG genotype had lower blood calcium levels and higher alkaline phosphate levels than patients with the GG genotype. The lumbar BMD T-score was -2.20 (-2.63, -0.32) in patients with the GG genotype, and it was significantly lower in patients with the RR+RG genotype (-2.53 (-3.70, -1.72) P=0.036). Patients with the R allele had a significantly higher incidence of hyperplasia (25.0%) and carcinomas (7.1%) than those with the GG genotype (5.3 and 0% respectively; P=0.025). The prevalence of osteoporosis and parathyroid carcinomas was higher in Chinese PHPT patients with the R allele.
CONCLUSION: The R990G polymorphism is most frequently present in the Chinese population and among patients with PHPT. Additional studies in the Chinese population are needed to elaborate the relationship between genetics and PHPT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23946278     DOI: 10.1530/EJE-13-0441

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  9 in total

1.  Calcium-sensing receptor polymorphisms increase the risk of osteoporosis in ageing males.

Authors:  Andrea Di Nisio; Maria Santa Rocca; Marco Ghezzi; Maurizio De Rocco Ponce; Stefano Taglianetti; Mario Plebani; Alberto Ferlin; Carlo Foresta
Journal:  Endocrine       Date:  2017-10-10       Impact factor: 3.633

2.  Polymorphisms of CASR gene increase the risk of primary hyperparathyroidism.

Authors:  X-M Wang; Y-W Wu; Z-J Li; X-H Zhao; S-M Lv; X-H Wang
Journal:  J Endocrinol Invest       Date:  2015-12-28       Impact factor: 4.256

3.  Genetic Polymorphisms and Kidney Stones Around the Globe: A Systematic Review and Meta-Analysis.

Authors:  Abdolreza Mohammadi; Alireza Namazi Shabestari; Leila Zareian Baghdadabad; Fatemeh Khatami; Leonardo Oliveira Reis; Mahin Ahmadi Pishkuhi; Seyed Mohammad Kazem Aghamir
Journal:  Front Genet       Date:  2022-06-30       Impact factor: 4.772

Review 4.  The G allele of CaSR R990G polymorphism increases susceptibility to urolithiasis and hypercalciuria: evidences from a comprehensive meta-analysis.

Authors:  Kang Liu; Xiaolan Wang; Jiaxin Ye; Chao Qin; Pengfei Shao; Wei Zhang; Jie Li; Changjun Yin
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

5.  Characteristics of patients operated for primary hyperparathyroidism at university hospitals in Türkiye: differences among Türkiye's geographical regions.

Authors:  Turkay Kirdak; Nuh Zafer Canturk; Nusret Korun; Gokhan Ocakoglu
Journal:  Ann Surg Treat Res       Date:  2016-06-30       Impact factor: 1.859

Review 6.  Diseases associated with calcium-sensing receptor.

Authors:  C Vahe; K Benomar; S Espiard; L Coppin; A Jannin; M F Odou; M C Vantyghem
Journal:  Orphanet J Rare Dis       Date:  2017-01-25       Impact factor: 4.123

7.  Radiofrequency Ablation of Parathyroid Glands to Treat a Patient With Hypercalcemia Caused by a Novel Inactivating Mutation in CaSR.

Authors:  Yu Hao; Zhikai Lei; Nanjing Shi; Lingying Yu; Weiqin Ji; Xianfeng Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-14       Impact factor: 5.555

8.  Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

Authors:  Sohyun Jeong; In-Wha Kim; Kook-Hwan Oh; Nayoung Han; Kwon Wook Joo; Hyo Jin Kim; Jung Mi Oh
Journal:  Drug Des Devel Ther       Date:  2016-07-08       Impact factor: 4.162

9.  The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.

Authors:  Jaruwan Ngamkam; Somratai Vadcharavivad; Nutthada Areepium; Titinun Auamnoy; Kullaya Takkavatakarn; Pisut Katavetin; Khajohn Tiranathanagul; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Sci Rep       Date:  2021-09-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.